Clinical Trial Update: Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for miransertib in PROS and Proteus Syndrome (MOSAIC) shows the study was terminated; results were posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pik3ca-related Overgrowth Spectrum
• Proteus Syndrome

Drugs mentioned

• Miransertib (Miransertib)

Snippet

Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Conditions: PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-03-31